Stay updated with breaking news from Poseidon Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.
Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.